← Leaderboards
John G. McHutchison
Scripps Research Institute
$191,527
Attributed
$191,527
Total exposure
11
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$191,527 · 11
By mechanism
M01$191,527 · 11
Top collaborators
No co-investigators on record.
Most similar at Scripps Research Institute
Same institution · by research overlap
- Juan C. De La Torre$34,810,527
- Francis Vincent Chisari$28,451,545
- Paul J Pockros$218,896
- Michael B Oldstone$35,619,947
- J. Lindsay Whitton$31,825,279
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchInterferon AlphaHepatitis CMicroorganism Disease ChemotherapyCombination ChemotherapyImmunotherapyRibavirinLiver Disorder ChemotherapyDrug Screening /EvaluationChronic Disease /DisorderHepatitis BHepatitis C VirusPolyethylene GlycolsDrug Administration Rate /DurationClinical TrialsAntiviral AgentsDosageReverse Transcriptase InhibitorsRelapse /RecurrenceHistocompatibility AntigensCytotoxic T LymphocyteLamivudine
Grant awards (20)
PEG INTERFERON ALFA 2B PLUS RIBAVIRIN FOR HEPATITIS C$0
M01 · FY2002 · RR
LOBUCAVIR VS ALPHA INTERFERON IN CHRONIC HEPATITIS B$0
M01 · FY2002 · RR
INTRON A VS INTRON A + RIBAVIRIN IN RELAPSED HEPATITIS C$0
M01 · FY2002 · RR
PEG IFN VS INTRON A FOR CHRONIC IFN NAIVE HEPATITIS C$0
M01 · FY2002 · RR
DOSE ESCALATION OF ORAL RIBAVIRIN &INTRON A FOR FAILED-IFN HEPATITIS C$0
M01 · FY2002 · RR
LOBUCAVIR IN CHRONIC HEPATITIS B PATIENTS WHO HAVE FAILED OR ARE IFN INTOLERANT$0
M01 · FY2002 · RR
COMPARISON OF INDUCTION TO INTRONA + RIBAVIRIN FOR HEPATITIS C$0
M01 · FY2002 · RR
ADEFOVIR DIPIVAXIL FOR TREATMENT OF CHRONIC HEPATITIS B INFECTION$0
M01 · FY2002 · RR
RESPONSE TO ANTIVIRAL THERAPY IN CHRONIC HEPATITIS C$0
M01 · FY2002 · RR
CONTINUOUS VS 24 WK COURSES OF INTRON A THERAPY FOR RELAPSED HEPATITIS C$27,361
M01 · FY2000 · RR
INTRON A VS INTRON A + RIBAVIRIN IN RELAPSED HEPATITIS C$27,361
M01 · FY2000 · RR
COMPARISON OF INTRON A + S-P AND ICN RIBAVIRIN CAPSULES IN CHRONIC HEPATITIS C$27,361
M01 · FY2000 · RR
PEG IFN VS INTRON A FOR CHRONIC IFN NAIVE HEPATITIS C$27,361
M01 · FY2000 · RR
DOSE ESCALATION OF ORAL RIBAVIRIN &INTRON A FOR FAILED-IFN HEPATITIS C$27,361
M01 · FY2000 · RR
LOBUCAVIR IN CHRONIC HEPATITIS B PATIENTS WHO HAVE FAILED OR ARE IFN INTOLERANT$27,361
M01 · FY2000 · RR
COMPARISON OF INDUCTION TO INTRONA + RIBAVIRIN FOR HEPATITIS C$27,361
M01 · FY2000 · RR
ADEFOVIR DIPIVAXIL FOR TREATMENT OF CHRONIC HEPATITIS B INFECTION$0
M01 · FY2000 · RR
RESPONSE TO ANTIVIRAL THERAPY IN CHRONIC HEPATITIS C$0
M01 · FY2000 · RR
PEG INTERFERON ALFA 2B PLUS RIBAVIRIN FOR HEPATITIS C$0
M01 · FY2000 · RR
LOBUCAVIR VS ALPHA INTERFERON IN CHRONIC HEPATITIS B$0
M01 · FY2000 · RR